DreaMed Diabetes Announces the Integration of Abbott’s FreeStyle Libre Data into DreaMed’sendo.digital Platform
The integration enables DreaMed’s thousands of endo.digital platform users to seamlessly receive data from Abbott’s FreeStyle Libre continuous glucose monitors (CGMs)
TEL AVIV, June. 20, 2024－DreaMed Diabetes today announced an integration with Abbott that enables the seamless data transfer of world-leading[1] FreeStyle Libre continuous glucose monitoring (CGM) technology into DreaMed’s endo.digital advanced clinical decision support system designed to assist healthcare professionals in the optimization of patient-specific insulin therapy for people with diabetes.
This completes another significant milestone of DreaMed’s vision to deliver a true end-to-end diabetes management platform, that includes not only market-leading breadth of diabetes device data acquisition, but also powerful AI-enhanced U.S. Food & Drug Administration cleared decision support combined with a patient app.
“I am very proud of our team and honored to partner with the market leader Abbott to help not only elevate patient care but also dramatically streamline provider workflow,” said Eran Atlas, founder and chief executive officer, DreaMed.
“Advances in diabetes technology have improved patient care, but manual data acquisition burdens clinicians and their staff,” said Moshe Phillip, M.D., Director of the Institute of Endocrinology and Diabetes at Schneider Children’s. “The seamless, cloud-based platform that DreaMed provides can help alleviate these burdens by integrating data, enabling providers the ability to offer better patient care with real-time information.”
About DreaMed:
DreaMed is a software company that uses AI to transform patient data into expert level treatment recommendations. Since partnering with Medtronic to pioneer the world’s first artificial pancreas, DreaMed has achieved five FDA clearances, and launched endo.digital, a decision support platform that automates the diabetes care pathway from end-to-end. The platform is compatible with the vast majority of diabetes devices on the market, integrates into the EMR, and is clinically proven. Furthermore, the platform has demonstrated significant improvements in workflow efficiency, and increased in practice revenue. For more information, visit www.dreamed.ai .
[1] Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.